Schoenberg Mark 4

What Happened
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), reported the sale of 10,000 shares on 2026-05-08 for a total proceeds of roughly $300,000. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.05; the filing reports a weighted-average price of $30.00.

Key Details

• Transaction date: 2026-05-08 (reported on Form 4 filed 2026-05-11). Filing appears timely (within required business-day window).
• Quantity and price: 10,000 shares sold; weighted-average price $30.00; individual trade prices ranged $30.00–$30.05.
• Aggregate value: approximately $300,000.
• Post-transaction holdings: not specified in the provided filing.
• Footnotes: sale executed under a pre-established Rule 10b5-1(c) trading plan adopted 08-15-2025 (F1). The weighted-average price reflects multiple trades; the filer will supply per-price breakdown upon request (F2).

Context
This was a sale executed under a 10b5‑1 plan, which is a prearranged trading program commonly used by insiders to sell shares according to a schedule and reduce timing concerns. Sales are often routine and do not necessarily indicate a change in the insider’s view of the company’s prospects.